At last, the real anxieties lurking behind what has come to be called the “Ambedkar cartoon” controversy are out in the open. It is hideously clear by now that MPs “uniting across parties” are acting as one only to protect themselves from public scrutiny, debate and criticism. It turns out, as some of us suspected all along, that the “sentiments” that have been “hurt” this time are the easily bruised...

Justice Markandey Katju's prescription for a regulated media regime is a misplaced step that can actually de-democratise the fourth estate. IT is open season on the political class and the news media. But then, again, it's more like a chase of one's own tail. A self-righteous, delusional, Anna-Baba NGO-ised fringe sets out to stigmatise politics and Members of Parliament; the news media salivate at the prospect and rush to provide...

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs. Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments...

Having watched from the ringside for many years now, I have no doubt in advising that the steering wheel must be firmly grasped by the government and direction given to policies that should be stable for at least the medium term. This is crucial for the growth of Indian pharma, a $20-billion industry growing at an average of 12% considering both domestic and export arenas. Price control: The biggest and most...

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...